TranS1 has obtained CE mark approval for its VEO minimally invasive lateral access fusion system for interbody fusions.
The VEO lateral fusion system, featuring two-stage retraction method that focuses on nerve visualization and then controlled retraction, is designed for direct visualization of the psoas muscles and adjacent nerves prior to muscle dissection.
To allow proper placement of the VEO lateral fusion system, radiopaque markers are located within the implants.
Full range of PEEK lateral interbody implants and various ergonomic instruments complements the VEO retractor.
TranS1 president and chief executive officer Ken Reali said, "We are excited to begin executing on our commercialization strategy in Europe as we enter the third quarter."
